Combination therapy reduces cardiovascular risk factors in people with type 2 diabetes
In people with type 2 diabetes, Xultophy® (insulin degludec/liraglutide) significantly reduced a number of risk factors associated with an increased risk of cardiovascular disease (CVD), compared to basal insulin.
A new post-hoc analysis of the DUAL II and DUAL V trials presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes (EASD 2017), shows that people treated with the insulin-liraglutide combination given by injection had significantly lower systolic blood pressure, total cholesterol and LDL-C and significant weight loss compared to people treated with basal insulin (insulin glargine U100 or insulin degludec). A small but statistically significant increase in heart rate was also observed.
Professor Tina Vilsbøll, Steno Diabetes Center Copenhagen, Denmark said, "People with type 2 diabetes have a higher risk of a heart attack or stroke compared to the general population, so reducing this risk as much as possible should be a central goal of treatment. I am very pleased to see the beneficial effects on cardiovascular risk markers.”
|Cardiovascular markers||DUAL II treatment difference vs insulin||DUAL V treatment difference vs insulin|
|Systolic blood pressure (mmHg)||-3.7 (-6.1, -1.3)*||-3.6 (-5.5,-1.6)*|
|Total cholesterol||1 (0.9, 1.0)*||1 (0.9, 1.0)*|
|LDL-cholesterol||0.9 (0.9,1.0)*||0.9 (0.9,1.0)*|
CVD is the principal cause of death and disability among people with type 2 diabetes globally, with approximately two-thirds of deaths in people with diabetes attributable to CVD. Treatments for type 2 diabetes should not only lower blood sugar levels but also aim to decrease CV risk.